Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alagebrium in Type 1 Diabetes with Microalbuminuria
NCT00557518Phase 2Terminated
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Nov 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in diabetic nephropathy (DN) comparing Alagebrium Arm with Placebo Arm (2 arms). Primary endpoint: Change from baseline in albumin excretion rate at 24 weeks. Started Nov 2007; status: terminated.
02
Drugs
alagebrium
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00557518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557518.